Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Expert perspective videos
BLENREP resources
Explore our range of BLENREP video content and downloadable resources
For GB healthcare professionals only.*
Table of contents
Managing triple-class relapsed/refractory multiple myeloma (RRMM)
The latest best practice in using BLENREP to treat triple-class refractory multiple myeloma, and the implications for patient care from key experts in the field.
The evolving treatment landscape and unmet needs in RRMM (16 mins)
Professor Graham Jackson discusses the evolution of triple-class refractory multiple myeloma and treatments, and addresses challenges faced with therapy today.
BLENREP clinical data review (14 mins)
Watch Dr Karthik Ramasamy review the latest DREAMM-2 clinical data.
Expert Insights: Panel discussion and Q&A (28 mins)
Join Professor Graham Jackson, Dr Bhuvan Kishore and Dr Karthik Ramasamy as they discussion RRMM treatment with BLENREP, including expert advice on setting up a BLENREP treatment plan.
The evolving treatment landscape and unmet needs in RRMM (12 mins)
Watch Dr Karthik Ramasamy discuss the current standard of care in triple refractory multiple myeloma, and the rationale for targeting B-cell maturation antigen.
BLENREP in triple-class RRMM: A clinical data review (14 mins)
Watch Dr Rakesh Popat present the DREAMM-2 study, including efficacy results, safety data, and how eye-related side effects were managed.
Expert Insights: Panel discussion and Q&A (11 mins)
Watch Dr Rakesh Popat, Miss Simona Degli Esposti and Dr Karthik Ramasamy as they discuss key topics about managing patients on BLENREP.
Managing eye-related side effects
Understand how to effectively manage eye-related side effects with BLENREP and the importance of collaboration with the multidisciplinary team (MDT).
Monitor, Minimise, Modify: The 3 Ms of managing eye-related side effect (24 mins)
Watch Miss Simona Degli Esposti and Dr Rakesh Popat as they explore the practicalities of managing eye-related side effects across the MDT.
Key experts describe their real-world experiences of BLENREP treatment in patients with triple-class refractory multiple myeloma.
Real-world patient case study: The practicalities of BLENREP treatment (13 mins)
See how Dr Bhuvan Kishore managed and monitored a patient receiving BLENREP, including the creation of a delivery plan with Opthalmologists, and how to approach eye-related side effects.
Real-world patient case study: Corneal AEs and patient QoL (13 mins)
Watch Dr Karthik Ramasamy describe how he successfully managed keratopathy in one of his patients receiving BLENREP and its impact on patient QoL.
Real-world patient case study: Managing a triple-class refractory patient on BLENREP (9 mins)
Dr Karthik Ramasamy discusses the challenges faced with treating a patient with RRMM and how to manage a patient receiving BLENREP.
Real-world patient case study: Working with Opthalmologists to manage patients (13 mins)
Watch Dr Rakesh Popat and Miss Simona Degli Esposti collaborate to monitor and manage patients on BLENREP treatment.
BLENREP summary of product characteristics
BLENREP prescribing information
BLENREP risk minimisation materials
EMC website
Do you have a question or want to talk to your local haematology Key Account Manager? Click below to fill in the enquiry form, and get in touch!
Understand how BLENREP works in multiple myeloma
Find out more about what BLENREP can offer your patients
*BLENREP is not commercially available in Northern Ireland.
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.1
Abbreviations
AE, adverse event; DREAMM-2, DRiving Excellence in Approaches to Multiple Myeloma; HCP, healthcare professional; MDT, multidisciplinary team; MoA, mode of action; QoL, quality of life; RRMM, relapsed/refractory multiple myeloma
References
- BLENREP Summary of Product Characteristics.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
© 2022 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
Third party trade marks are the property of their respective owners
March 2023 | PM-GB-BLM-WCNT-220007 (V3.0)
